MSD Animal Health (known as Merck Animal Health in the U.S. and Canada) announced Nov. 14 that it has signed an agreement to acquire Vilsan Pharmaceuticals, a division of Vimar Group, based in Turkey.

Vilsan Pharmaceuticals, the largest privately held producer of animal health products in Turkey, has an extensive portfolio of pharmaceutical products, notably for ruminants, as well as a manufacturing facility.

“We are excited about the opportunity to expand and complement our MSD Animal Health portfolio with products from Vilsan Pharmaceuticals, which will bring value and new options to our customers in this growing region,” said Philippe Houffschmitt, general manager of MSD Animal Health Turkey.

The agriculture industry is an important driver of the economy in Turkey, the second most populous country in Europe. Turkey is experiencing robust growth in the value of animal production, driven by increased demand for protein, the announcement said.

“We are very pleased to join with MSD Animal Health to build upon our 30-year commitment to advance the health of animals,” Vilsan Pharmaceuticals chief executive officer Burhan Haci said. “Their expertise, commercial reach and worldwide network, combined with our portfolio and production capacity, represents a tremendous opportunity to serve producers and veterinarians in this region.”

Terms of the agreement were not disclosed. The agreement is subject to regulatory review and certain closing conditions and is expected to close in the coming months.

For more than a century, MSD, a leading global biopharmaceutical company, has been bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health is the global animal health business unit of MSD. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets.